Edition:
United Kingdom

Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

24.40USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$24.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
121,266
52-wk High
$33.21
52-wk Low
$21.35

Chart for

About

Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and... (more)

Overall

Beta: --
Market Cap(Mil.): $828.20
Shares Outstanding(Mil.): 30.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.75 16.58
EPS (TTM): -- -- --
ROI: -- 3.21 10.60
ROE: -- 4.54 14.19

BRIEF-Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary, All Secondary Endpoints In Two Phase 2 Clinical Trials For Common Warts

* ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS

08 Jan 2018

Aclaris's drug to treat common skin growth gets FDA nod

Aclaris Therapeutics Inc's drug to treat a common kind of skin growth called seborrheic keratoses received approval from the U.S. Food and Drug Administration, the company said on Friday.

15 Dec 2017

UPDATE 2-Aclaris's drug to treat common skin growth gets FDA nod

Dec 15 Aclaris Therapeutics Inc's drug to treat a common kind of skin growth called seborrheic keratoses received approval from the U.S. Food and Drug Administration, the company said on Friday.

15 Dec 2017

Aclaris's drug to treat common growth on skin gets FDA nod

Dec 15 Aclaris Therapeutics Inc said on Friday the U.S. Food and Drug Administration (FDA) had approved its topical drug to treat seborrheic keratoses, growths on the skin that are harmless but affect millions of Americans.

15 Dec 2017

BRIEF-Aclaris Therapeutics Receives FDA Approval For Eskata For Treatment Of Raised SKs

* ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS)

15 Dec 2017

BRIEF-Aclaris Therapeutics wins patent in Japan for treating hair loss

* Aclaris Therapeutics announces the allowance of a U.S. patent application and issuance of a Japanese patent covering tofacitinib for treating hair loss disorders Source text for Eikon: Further company coverage:

24 Oct 2017

BRIEF-Deerfield Mgmt reports 5.90 pct passive stake in Aclaris Therapeutics

* Deerfield Mgmt, L.P. reports 5.90 pct passive stake in Aclaris Therapeutics Inc as of Sept 29 - SEC filing Source text: (http://bit.ly/2wKeWrl) Further company coverage:

10 Oct 2017

BRIEF-Aclaris Therapeutics announces publication of phase 2 trial data of A-101 for treatment of facial seborrheic keratosis

* Aclaris Therapeutics announces publication of data from phase 2 clinical trial of A-101 topical solution for treatment of facial seborrheic keratosis

19 Sep 2017

BRIEF-Aclaris Therapeutics announces issuance of two U.S. Patents covering JAK inhibitors for treating hair loss disorders

* Aclaris Therapeutics announces issuance of two U.S. Patents covering JAK inhibitors for treating hair loss disorders Source text for Eikon: Further company coverage:

05 Sep 2017

BRIEF-Vivo Ventures VII LLC reports 9.5 pct stake in Aclaris Therapeutics

* Vivo Ventures VII LLC reports 9.5 percent stake in Aclaris Therapeutics Inc as of March 15, 2017 - SEC filing

14 Aug 2017

Competitors

  Price Chg
RXi Pharmaceuticals Corp (RXII.OQ) $4.69 --

Earnings vs. Estimates